[The primary applications of ¹⁵³Sm-EDTMP plus chemotherapy in the treatment of bone metastasis of lung cancer]

Objective To study the clinical effects of 153Sm-EDTMP plus chemotherapy in the treatment of bone metastasis of lung cancer. Methods One hundred and ten lung cancer patients with one metastasis [male 82 and female 28, aged from 32 to 76 yrs; squamous cell carcinoma 28, adenocarcinoma 27, small cell lung cancer (SCLC) 7, mix type 41, alveolar carcinoma 7] who did not undergo an operation were entered into this study. The patients were divided into 3 groups: 153Sm-EDTMP therapy only (37 cases), 153Sm-EDTMP plus chemotherapy after 3 days (42 cases), 30 days after chemotherapy plus 153Sm-EDTMP (31 cases). The dosages of 153Sm-EDTMP ranged from 1 111 to 2 660 MBq. The patients with SCLC were adapted CCNU, MTX and CTX; those with non-small cell lung cancer (NSCLC) were adapted MMC, VCR and DDP. Statistic analysis of the data was performed by χ2 test. Results Total pain relief rate for 153Sm-EDTMP only was 89.2% , for 153Sm-EDTMP plus chemotherapy was 92.8%, and for chemotherapy plus 153 Sm EDTMP was 90.3% . The foci disappeared in 9 cases with 153Sm-EDTMP only, in 12 cases with 153Sm-EDTMP plus chemotherapy, and in 9 cases with chemotherapy plus 153Sm-EDTMP. The 1 year survival rate was 29.7%(11/37) by 153 Sm only, 40.5%(17/42) by 153 Sm plus chemotherapy, 38.7%(12/31) by chemotherapy plus 153Sm-EDTMP. Conclusion 153Sm-EDTMP plus chemotherapy is effective in the treatment of bone metastasis of lung cancer. DOI: 10.3779/j.issn.1009-3419.2002.04.09